Traders bought shares of Chemours Company (The) (NYSE:CC) on weakness during trading hours on Thursday. $284.96 million flowed into the stock on the tick-up and $35.50 million flowed out of the stock on the tick-down, for a money net flow of $249.46 million into the stock. Of all stocks tracked, Chemours had the 3rd highest net in-flow for the day. Chemours traded down ($0.31) for the day and closed at $51.40

A number of brokerages recently weighed in on CC. BidaskClub downgraded Chemours from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Argus reissued a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Chemours in a research note on Thursday, August 10th. UBS raised Chemours from a “sell” rating to a “neutral” rating and raised their price objective for the company from $36.00 to $50.00 in a research note on Monday, August 7th. Zacks Investment Research raised Chemours from a “hold” rating to a “strong-buy” rating and set a $61.00 price target on the stock in a research report on Tuesday, October 3rd. Finally, J P Morgan Chase & Co lifted their price target on Chemours to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 4th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Chemours presently has a consensus rating of “Buy” and a consensus target price of $53.89.

The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. The stock has a market cap of $9,522.94, a PE ratio of 18.24, a P/E/G ratio of 0.89 and a beta of 3.41.

Chemours (NYSE:CC) last issued its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.11. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. Chemours had a return on equity of 116.80% and a net margin of 4.86%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 EPS. sell-side analysts expect that Chemours Company will post 3.73 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Monday, November 20th will be given a $0.03 dividend. This represents a $0.12 annualized dividend and a yield of 0.23%. The ex-dividend date is Friday, November 17th. Chemours’s dividend payout ratio is currently 8.28%.

In other news, SVP David C. Shelton sold 19,000 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $53.68, for a total transaction of $1,019,920.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider E Bryan Snell sold 13,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $49.35, for a total value of $641,550.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,183 shares of company stock worth $3,361,716. Company insiders own 1.14% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Chemours by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after purchasing an additional 905,038 shares during the period. Renaissance Technologies LLC increased its position in shares of Chemours by 10.3% during the second quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock valued at $126,736,000 after purchasing an additional 310,800 shares during the period. Bank of New York Mellon Corp increased its position in shares of Chemours by 7.9% during the third quarter. Bank of New York Mellon Corp now owns 2,371,909 shares of the specialty chemicals company’s stock valued at $120,042,000 after purchasing an additional 173,523 shares during the period. JPMorgan Chase & Co. increased its position in shares of Chemours by 11.9% during the third quarter. JPMorgan Chase & Co. now owns 2,201,287 shares of the specialty chemicals company’s stock valued at $110,969,000 after purchasing an additional 234,705 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in shares of Chemours by 126.5% during the second quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock valued at $67,843,000 after purchasing an additional 999,380 shares during the period. Institutional investors and hedge funds own 74.41% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/02/investors-buy-chemours-cc-on-weakness.html.

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.